首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung
【24h】

KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung

机译:一系列选定的EGFR,KRAS和EML4-ALK野生型肺腺癌细胞学标本中的KIF5B / RET融合基因分析

获取原文
获取原文并翻译 | 示例
           

摘要

A new RET fusion gene has been recently described in a subset of non-small cell lung cancer (NSCLC) identified by specific clinico-pathologic characteristics. This transforming gene arise from the fusion of KIF5B and the RET proto-oncogene, and it is mutually exclusive with EGFR, KRAS and EML4/ALK alterations. For this reason it could represent a putative target for specific inhibitory drugs and its evaluation could be necessary in the future daily molecular characterization of NSCLCs. One of the major challenge in diagnostic molecular pathology is to optimize genotyping tests with the minimally invasive techniques used to acquire diagnostic tumor tissue or cells. This is a significant relevant issue for approximately 60% of NSCLC patients presenting with unresectable disease, where the only pathologic materials available for diagnostic use are small biopsy or cytological specimens. Thus, the aim of this study was to verify the possibility to use RNA purified from cytological specimens to perform KIF5B/RET gene fusion expression analysis. Accordingly, we looked for the presence of the rearrangement in formalin fixed paraffin embedded tissues (FFPETs) and cytological specimens (CSs) of a selected series of "triple-marker" negative adenocarcinomas. The tests conducted revealed the presence of 1 positive patient for variant 1 of KIF5B/RET among the 49 analyzed. The presence of this fusion transcript was found in both FFPET and CS of the same patient demonstrating that the RNA obtained from minimally invasive techniques is perfectly suitable for this kind of tests. The presence of the rearrangement was also confirmed by FISH analysis.In conclusion, our findings confirm that the performance of cytology-based molecular testing for KIF5B/RET rearrangements is at least as effective as histology-based analysis, both with regard to the success rate for nucleic acid isolation and the ability to detect gene alterations.
机译:最近在非小细胞肺癌(NSCLC)的一个子集中已经描述了一种新的RET融合基因,该子集通过特定的临床病理特征进行了鉴定。该转化基因来自KIF5B和RET原癌基因的融合,与EGFR,KRAS和EML4 / ALK改变互斥。因此,它可能代表特定抑制药物的假定靶标,并且其评估在将来非小细胞肺癌的日常分子鉴定中可能是必要的。诊断分子病理学的主要挑战之一是使用用于获取诊断性肿瘤组织或细胞的微创技术优化基因分型测试。对于大约60%患有不可切除疾病的NSCLC患者而言,这是一个重大的相关问题,其中唯一可用于诊断的病理材料是小型活检或细胞学标本。因此,本研究的目的是验证使用从细胞学标本中纯化的RNA进行KIF5B / RET基因融合表达分析的可能性。因此,我们寻找福尔马林固定石蜡包埋组织(FFPETs)和一系列“三标记”阴性腺癌的细胞学标本(CSs)中是否存在重排。进行的测试显示,在分析的49位患者中,有1位阳性患者出现了KIF5B / RET变异体1。在同一位患者的FFPET和CS中均发现了该融合转录本的存在,这表明从微创技术获得的RNA非常适合此类测试。通过FISH分析也证实了重排的存在。总而言之,我们的发现证实了基于细胞学的KIF5B / RET重排分子检测的性能至少与基于组织学的分析一样有效,无论是在成功率方面用于核酸分离和检测基因改变的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号